Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Want to cut your energy bills? Here’s how five experts are doing it 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
SALT LAKE CITY, March 08, 2016 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the Barclays Capital 2016 Global Healthcare Conference at 2:35 p.m. EDT on March 15, 2016, at Loews Miami Beach Hotel in Miami Beach, Florida. The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
